- Home
- CNTB vs KPTI Comparison
CNTB vs KPTI Comparison
Compare CNTB & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- KPTI
- Stock Information
- Founded
- CNTB 2012
- KPTI 2008
- Country
- CNTB United States
- KPTI United States
- Employees
- CNTB N/A
- KPTI N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- KPTI Health Care
- Exchange
- CNTB Nasdaq
- KPTI Nasdaq
- Market Cap
- CNTB 93.9M
- KPTI 102.4M
- IPO Year
- CNTB 2021
- KPTI 2013
- Fundamental
- Price
- CNTB $2.80
- KPTI $5.50
- Analyst Decision
- CNTB Strong Buy
- KPTI Strong Buy
- Analyst Count
- CNTB 3
- KPTI 6
- Target Price
- CNTB $8.33
- KPTI $22.17
- AVG Volume (30 Days)
- CNTB 591.8K
- KPTI 107.9K
- Earning Date
- CNTB 11-12-2025
- KPTI 11-03-2025
- Dividend Yield
- CNTB N/A
- KPTI N/A
- EPS Growth
- CNTB N/A
- KPTI N/A
- EPS
- CNTB N/A
- KPTI N/A
- Revenue
- CNTB $762,000.00
- KPTI $142,530,000.00
- Revenue This Year
- CNTB N/A
- KPTI $4.87
- Revenue Next Year
- CNTB $453,067.90
- KPTI $9.20
- P/E Ratio
- CNTB N/A
- KPTI N/A
- Revenue Growth
- CNTB N/A
- KPTI N/A
- 52 Week Low
- CNTB $0.51
- KPTI $3.51
- 52 Week High
- CNTB $3.28
- KPTI $13.20
- Technical
- Relative Strength Index (RSI)
- CNTB 68.76
- KPTI 44.20
- Support Level
- CNTB $1.49
- KPTI $5.35
- Resistance Level
- CNTB $3.28
- KPTI $6.50
- Average True Range (ATR)
- CNTB 0.33
- KPTI 0.42
- MACD
- CNTB 0.12
- KPTI 0.01
- Stochastic Oscillator
- CNTB 73.01
- KPTI 33.73
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.